公开(公告)号：US11168147B2

公开(公告)日：2021-11-09

申请号：US16472646

申请日：2017-12-21

申请人： Novartis AG

发明人： Maximilian Aigner ,  Alexander Wolfgang Koch ,  Markus Waldhuber

IPC分类号： C07K16/36 ,  C07K16/40

摘要： The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20240189439A1

公开(公告)日：2024-06-13

申请号：US18454457

申请日：2023-08-23

申请人： Novartis AG

发明人： Matthew Burger ,  Joseph Anthony D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles ,  Christian Kunz ,  Markus Waldhuber

IPC分类号： A61K47/68 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18

CPC分类号： A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

摘要： This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US11492402B2

公开(公告)日：2022-11-08

申请号：US16601070

申请日：2019-10-14

申请人： NOVARTIS AG

发明人： Verena Brand ,  Dominik Feuerbach ,  Fabrizio Gasparini ,  Nathalie George ,  Eveline Schaadt ,  Derya Shimshek ,  Honnappa Srinivas ,  Markus Waldhuber ,  Rainer Wilcken

IPC分类号： C07K16/28 ,  A61P25/28 ,  A61K39/395 ,  A61K39/00 ,  C12N7/00 ,  C12N15/70

摘要： The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

公开(公告)号：US12012464B2

公开(公告)日：2024-06-18

申请号：US17450122

申请日：2021-10-06

申请人： NOVARTIS AG

发明人： Maximilian Aigner ,  Alexander Wolfgang Koch ,  Markus Waldhuber

IPC分类号： C07K16/36 ,  C07K16/40

CPC分类号： C07K16/40 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US11779649B2

公开(公告)日：2023-10-10

申请号：US16718866

申请日：2019-12-18

申请人： Novartis AG

发明人： Matthew Burger ,  Joseph Anthony D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles ,  Christian Kunz ,  Markus Waldhuber

IPC分类号： A61K47/68 ,  A61P35/00 ,  A61K31/4745 ,  C07K16/18 ,  A61K45/06

CPC分类号： A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

摘要： This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.